Background/Aim: Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver for which a curative therapy is still lacking. The aim of this preclinical study was to assess if down regulation of host immunity by regulatory dendritic cells (DC) bears therapeutic implications in a murine model of PBC.
INTRODUCTION
Primary biliary cirrhosis (PBC) is a chronic progressive inflammatory liver disease that leads to the immune-mediated destruction of small and medium-size intrahepatic bile duct, progressive cholestasis and eventually, fibrosis and cirrhosis of the liver. [1] [2] [3] The serologic hallmark of PBC is the presence of high-titer serum antimitochondrial autoantibodies (AMA), although the role of AMA in the pathogenesis and progression of PBC is still elusive. 4 There is no curative therapy for PBC, although ursodeoxycholic acid (UDCA) is now widely used to treat patients with PBC. 5, 6 A long-term follow-up study in a cohort of 225 patients reported 10-year survival without liver transplantation to be significantly higher in UDCA-treated patients compared with survival predicted by the Mayo model. 7 However, a meta-analysis of 11 randomized trials could not confirm a significant effect of UDCA on survival and incidence of liver transplantation. 8 The peroxisome proliferator-activated receptor α-agonist, bezafibrate, has been reported to improve serum liver tests in PBC and this drug should undergo more extensive evaluation in patients with PBC. 9 In addition, corticosteroids and other immunosuppressive agents have been evaluated for therapeutic use in PBC, however, these drugs have not been shown to markedly improve the natural course of the disease or were associated with significant toxicity during long-term treatment. 3 Taken together, new and innovative therapy should be developed for PBC.
In this regard, we provided attention to immune therapy as PBC is an immune-mediated disease. Dendritic cells (DC), the most potent antigen-presenting cell, have recently used either to upregulate or down regulate host immunity in various pathological conditions and some of these approaches seem to have therapeutic potential. 10 As an inflammatory microenvironment prevails in the liver of PBC patients, we assumed that regulatory DC that down regulate host immunity may be a choice of therapy for PBC. In fact, regulatory DC has been used in different animal models of human diseases with potential therapeutic promises. [11] [12] [13] [14] [15] [16] [17] [18] In this study, we checked the therapeutic efficacy of regulatory DC and antigen-specific regulatory DC in an animal model of PBC. The outcome of this pilot study may be used for development of better therapeutic regimen for PBC and other autoimmune diseases.
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MATERIALS AND METHODS
Murine Model of PBC
An animal model of PBC was prepared by injecting 5 mg/kg of polyinosinic-polycytidylic acid (poly I:C, Sigma, St. Lous, MO, USA) twice a week in female C57BL/6 mice, exactly as described by us in a previous communication. 19 Control mice received 200 µl of phosphate-buffered saline (PBS). They were maintained separately at the animal house of Ehime University, School of Medicine, Ehime, Japan, under controlled conditions (22°C, 55% humidity, and 12-hour day/night), and were fed freely supplied standard laboratory chow and water. All animals received adequate humane care according to good laboratory practice guidelines. The Committee of Animal Experimentation, Ehime University School of Medicine, Japan approved this study protocol.
Histopathology and Immunohistochemical Examination
To assess the extent of infiltration of inflammatory mononuclear cells, formalin-fixed, paraffin-embedded liver tissues were used for histological evaluation. The area of the liver specimens, the number of portal tracts, and the extent of cell infiltration were estimated using a combination of a digital camera and imaging tools, as described. 19 
Detection of Autoantibodies
The existence of autoantibodies was examined in HEp-2 cells using the commercially available fluoro HEPANA Test system (MBL, Nagoya, JAPAN), exactly as described. 20 After reacting HEp-2 cells with sera, Alexa Fluor 555conjugated polyclonal goat antimouse immunoglobulin (Molecular Probes Inc. Eugene, OR) was used as a secondary antibody. Based on staining pattern, antinuclear antibody (ANA), AMA, and both ANA and AMA were detected in various sera from mice.
Production of Regulatory DC
Immature bone marrow (BM)-derived DC were prepared by culturing bone marrow cells with murine granulocytemacrophage colony stimulating factor (GM-CSF, 5 ng/ml, R&D systems Inc, Minneapolis, MN, USA) and murine interleukin (IL)-4 (5 ng/ml, R&D systems Inc) for 7 days. 11 To prepare regulatory DC, bone marrow DC were cultured with lipopolisaccharides (LPS, 1 µg/ml, InvitroGen, Carlasbad, CA, USA) and IL-10 (20 ng/ml, R&D systems Inc) in RPMI 1640 plus 10% fetal calf serum for 48 hours. In some studies, PDC-pulsed regulatory DC were prepared by culturing bone marrow DC with LPS, IL-10 and PDC (1 µg/ml, Sigma). The cells retrieved and washed in PBS before administration to mice.
Therapeutic Protocol
Production of animal model of PBC and therapeutic regimen have been shown in Figure 1 . Several female C57BL/6 were injected with poly I:C, twice in a week for 28 weeks. Some of the poly I:C-injected mice received regulatory DC or PDC-pulsed regulatory DC for 3 times (8, 12 and 20 weeks after commencement of poly I:C administration). Sera were collected from all mice at 16 and 28 weeks. Mice were also killed at 16 and 28 weeks after starting poly I:C administration to assess the extent of liver damages.
RESULTS
Mice Model of PBC
A mice model of PBC was developed due to administration of poly I:C for 8 weeks and the extent of liver damages progressed along with time. As shown in Figures 2A to C, infiltration of mononuclear cells were observed around portal area ( Fig. 2A) , around biliary epithelia ( Fig. 2B ) and in hepatic parenchyma (Fig. 2C ) at 16 weeks after commencing administration of poly I:C in female C57BL/6 mice. In addition, AMA and ANA were found in the sera of all mice injected with poly I:C (Figs 3A to C). 
IL-10 Production by PDC-pulsed Regulatory DC
Almost no IL-10 was produced by bone marrow DC in spontaneous culture. However, abundant amounts of IL-10 (>1000 pg/ml) were produced by regulatory DC and PDCpulsed regulatory DC in the supernatant of all cultures.
Role of Regulatory DC on Inflammatory Mucosal Milieu of Animal Model of PBC
Three administrations of regulatory DC and PDC-pulsed regulatory DC caused significantly reduced infiltration of inflammatory cells in 4 of 5 PBC model mice. The extent of infiltration of mononuclear cells of representative PBC model mice has been shown in Figure 4 .
We did not mark any significant difference about cell infiltration in PBC mice due to administration of regulatory DC or PDC-pulsed regulatory DC (data not shown).
Role of Regulatory DC on Serum AMA Levels
AMA was seen in PBC model mice due to when these were examined on 16 and 28 weeks after start of poly I:C administration. Injection with regulatory DC and PDC-pulsed regulatory DC could not cause negativity of AMA in any mice.
DISCUSSION
As present understandings about pathogenesis of chronic liver diseases are broadening, it seems that new and innovative types of therapeutic approaches would be required for containment of these pathological conditions. Immune therapy represents a novel and evidence-based type therapy in this context. This is especially true for autoimmune liver diseases because there is no curative therapy for these lesions. Almost of types of therapy for PBC is endowed with limited clinical efficacy.
In this study, we have shown that regulatory DC that is capable of inducing immune tolerance in vivo may be an alternate therapeutic approach against PBC. In fact, we have already found that DC are involved in variable manners in the pathogenesis of PBC. Yamamoto et al from our laboratory have shown that DC in PBC patients show impaired functional capacity that may be related to breakdown of self tolerance in PBC. 21 On the other hand, study from our laboratory has also shown that the anti- inflammatory property of bezafibrate in PBC is mediated through impaired anti-inflammatory action of DC. 22 Administration of regulatory DC and PDC-pulsed regulatory DC but not BM DC caused reduced accumulation of inflammatory cells in the portal area and hepatic parenchyma. However, a significant improved capacity of PDC-pulsed DC over unpulsed regulatory DC could not be substantiated in this study. There may be several reasons for this. PDC represents a PBC-related antigen because almost all patients with PBC show antibody to PDC or its epitopes, 23 even if they are AMA-negative. PDC-specific antibody has shown diagnostic utility in PBC. But, PDC may not be a target antigen of immune-mediated damages of PBC. Thus, future study using other PBC-related antigen pulsed regulatory DC may be a better therapeutic choice. In addition, we have used only one dose of PDC and kinetics of DC numbers for therapeutic effects in murine PBC model has not been explored. Studies would be required to assess other PBC-related antigens and different doses of PDC and DC to prepare antigen-specific regulatory DC for therapeutic purposes. However, treatment with regulatory DC clearly showed their anti-inflammatory activities, but, the levels of AMA negativity could not be attained by DC-based immune therapy. Although little is known about genesis of AMA and inflammatory microenvironment in PBC, it seems that they may be independently regulated. This is also supported from clinical data that have shown that AMA titers have no role in disease progression in PBC patients. DC-based immune therapy has been applied in several clinical conditions, either to upregulate host immunity or to down regulate that to achieve therapeutic efficacy. 10 However, a clinically acceptable protocol is yet to be developed. The
